|
Differential diagnostic technique and therapeutic approach to night eating syndrome Differential therapy is conducted depending on the number of night meals per a week. Sertraline in a dose of 100 mg is prescribed to the patients having two or less night meals per a week after going to bed and referred to a group of those with primarily evening manifestations of night eating syndrome. Agomelatine in a dose of 25 mg a day is prescribed to the patients having three or more night meals after going to bed and referred to a group of those with primarily night manifestations of night eating syndrome. The treatment continues until stable remission is achieved and further for 6 months. |
|
|
Method of external treatment of skin mycosis Loci of skin affection are successively processed first with eliminating solution, which represents 10-20% hypertonic solution of sodium chloride, then - 1% water solution of carbol fuchsin and after 10-15 minutes composition, which consists of 20-30 parts of tisolium and 80-70 parts of antimycotic, selected from the group: pimafucin, travogen, fungoterbine-neo, zalain, is applied, with processing being carried out twice per day for 14 and more days, daily alternating all 5 mentioned antimyotics in composition. |
|
Method of treating cardiovascular diseases Invention refers to pharmaceutical industry and represents a pharmaceutical dosage form for treating cardiovascular diseases and introduced once a day, containing a combination of fixed doses of metoprolol or its pharmaceutically acceptable salt in the sustained-release form, amlodipine, or valsartan, or olmesartan, or lisinopril, or enalapril, or their pharmaceutically acceptable salts, and one or more speed-control polymeric excipients containing cellulose polymers or their derivatives, and acrylic acid polymers or their derivatives, which form two layers on metoprolol or their pharmaceutically acceptable salt,wherein the dosage form possesses such a solution profile that less than 6% of metoprolol or its pharmaceutically acceptable salt releases for 1 hour. |
|
|
Pharmaceutical compositions of cocrystals of tramadol and coxibs Claimed invention relates to peroral pharmaceutical compositions, containing cocrystal of (rac)-tramadol-HCL - celecoxib (1:1) and at least one polymer solubility enhancer. Polymer solubility enhancer is selected from the group of graft copolymer of polyvinylkaprolactam-polyvinylacetate-polyethyleneglycol, cyclodextrin, copovidone and povidone. Also described is method of obtaining pharmaceutical composition, containing tramadol and celecoxib cocrystal. |
|
Method of treating essential arterial hypertension at background of obesity Invention relates to medicine, namely to cardiology, and deals with the treatment of essential arterial hypertension at the background of obesity. For this purpose realised is complex treatment, which includes the introduction of candesartan 8 mg/day, amlodipine 5 mg/day, indapamide 2.5 mg/day and sibutramine 10 mg/day in a combination with daily dosed 1-2 km walking for 1 month with the further increase of the distance to 3 km. The patient is taught to calculate the calorie content of the daily diet and control the treatment result by measuring the level of arterial pressure 2 times per week and determining the circumference of the waist and hips, as well as the body weight index 1 time per week on their own. |
|
|
Method for prevention of aggravated recurrent rhinosinusitis Method for prevention involves the three-week stress-protection therapy, diet therapy, omega 3 fatty acid deficiency therapy, vitamin therapy, probiotic therapy, probiotic-like therapy, antioxidant therapy, and local immunocorrective therapy. |
|
|
Using acid lysosome lipase for treating acid lysosome lipase deficiency in patients Invention refers to medicine and can be used for treating a human patient suffering acid lysosome lipase (ALL) deficiency. That is ensured by administering human recombinant ALL into the above human patient in an amount effective to normalise hepatic transaminase in serum or blood. The above human recombinant ALL is administered once approximately every 7 days to once approximately every 30 days, and the above dose is adequate to reducing the hepatic involvement in the above human patient. |
|
Method of assessing clinical course of acute biliary pancreatitis Patient is interviewed and undergoes biochemical tests and ultrasonic examination. That is followed by fibrogastroduodenoscopy involving parapapillary block within a duodenal papilla at 10 mm from the mouth and formation of a first submucosal depot of 0.5% Novocaine 10 ml and 4% gentamycin 2 ml in the 9 o'clock position. In the 15 o'clock position, a second submucosal depot of 2% drotaverin 2 ml and 1% dimedrol 2 ml is formed. If observing pain management for 10 minutes, the mild clinical course of acute biliary pancreatitis is diagnosed, whereas no pain management enables diagnosing the severe clinical course of acute biliary pancreatitis. |
|
Co-crystals of tramadol and coxibs Claimed invention relates to novel co-crystal, containing (rac)-tramadol HCl and celecoxib, with respective molecular ratio 1:1. Co-crystal can be used for treating pain, preferably acute pain, chronic pain, neuropathic pain, noticetive pain, minor and from severe to moderate pain, hyperalgesia, pain, associated with central sensitisation, allodynia or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia; rheumatois arthritis, ankylosing spondilitis, glenohumeral periarthritis or ischias. Co-crystal is characterised by peaks of powder X-ray diffraction, obtained with application of copper (CuKα1 1.54060 E), and irradiation and absorption bands of infrared spectra. Co-crystal has orthorhombic elementary cell with the following dimensions: a=11.0323 (7) E,b=18.1095 (12) E,c=17.3206 (12) E, as well as endothermic acute peak, corresponding to melt point, with start at 164°C. |
|
Method of treating chronic pain syndrome Suppositories, containing uniformly distributed in one suppository recombinant human interferon-alpha-2b in an amount of 400000-600000 IU and immunoglobulins IgA, IgM and IgG in an amount of 0.1-0.3 g, are additionally rectally introduced as the second medication to an adult patient in case of the long-term introduction of an opioid-containing medication. The dose constitutes 2-3 suppositories 2-3 times per day with the reduction of the daily dose by 1-3 suppositories in case of the reduction of pain sensation to 2-3 points by a ten-point scale and expressed sedation. If pain sensation increases to 6-8 points by the ten-point visual analogue scale, the daily dose is increased by 1-3 suppositories. |
|
|
Method for correction of crisis course of hypertensive disease and abdominal obesity Invention refers to medicine, namely to therapy and endocrinology, and concerns the correction of the crisis course of hypertensive disease and abdominal obesity. To this effect, Moxogamma 200-400 mcg/day and Reduxin 18-30 mg/day are administered with underlying a therapy of the angiotensin converting enzyme inhibitor lisinopril. The preparations are administered in two stages - in the morning and 6 or 7 hours later; Moxogamma is first to be administered, and Reduxin is administered 40-60 min later. |
|
Method for performing dental interventions in patients suffering acute stroke Performing a dental intervention in the patients suffering an acute stroke requires the oral administration or injections of a broad-spectrum antibiotic after examining the mouth or determining the extent of the dental intervention extent 30-60 minutes before the expected intervention. The patient is placed in a dental chair in a reclining posture at an angle of 35-50 degrees; a blood pressure is measured, and if the measured systolic pressure is 135-145 mm Hg, the dental intervention is performed. The dental intervention involves blood pressure monitoring, while the conduction anaesthesia is performed with 3% mepivacaine in a combination with the infiltration anaesthesia with 4% articaine with epinephrine 1:200,000 in a quantitative ratio 3:1. |
|
|
Pharmaceutical compositions for treating parkinson's disease Invention refers to medicine and represents a pharmaceutical composition for treating Parkinson's disease, containing a pharmaceutically acceptable carrier and a combination of flat doses of controlled release pramipexole and controlled release rasagiline; the above combination of flat doses contains pramipexole in an amount of 0.06 mg to less than 1.5 mg and rasagiline in an amount of 0.05 mg to less than 1.0 mg. |
|
Pharmaceutical compositions and oral dosage forms of levodopa prodrug and methods of using Invention refers to medicine and represents pharmaceutical compositions and oral dosage forms including granules prepared by wet granulation at a great shear force and containing an anhydrous crystalline (2R)-2-phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and C6-18 alkylsulphate. The invention also consists in methods of treating Parkinson's disease, schizophrenia, cognitive disorder, restless leg syndrome, periodic limb movement disorder, delayed dyskinesia, Huntington disease, hypertension and daytime sleepiness by administering a therapeutically effective amount of the pharmaceutical composition or dosage form into the patient. |
|
Amine derivatives and their use for treatment of ophthalmological diseases and illnesses Invention relates to new amine derivatives of the following structural formula: |
|
Method for preparation of patient for glaucoma surgery 1-1.5 hours before the surgery, the selective β-adrenergic blocker Betaloc is injected in an amount of 0.3-0.5 ml subconjunctivally in an upper semi-circle of the eyeball in accordance with 10 to 2 o'clock of a clock face. Then, 30-40 minutes before the surgery, 50% analgin 2.0 ml, 1% dimedrol 1.0 ml, seduxen 2.0 ml are injected intramuscularly. The surgery is immediately preceded by a subtenon block with 2% naropin 1.5 ml. |
|
|
Treating and/or preventing overweight and/or obesity related disorders, including type II diabetes mellitus are/is ensured by using a pharmaceutical composition containing metformin and its salts and sibutramine and its salts as ingredients in the following daily dose: sibutramine and its salts of 10 or 15 mg, metformin and its salts of 850 or 1700 mg, microcrystalline cellulose of 158.5 or 153.5 mg. There are also presented: usage and a method of treating and/or preventing the overweight and/or obesity related disorders. |
|
Method for providing higher efficacy and safety of ultrafast opioid detoxification What is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours. |
|
|
Invention refers to medicine, namely to gastroenterology and endocrinology, and concerns treating patients suffering from dyspepsia syndrome in a combination with overweight. That is ensured by therapy with preparations improving metabolism, promoting weight loss and fat absorption, as well as antidepressants. The therapy is differentiated taking into account an anxiety level (HARS) and a depression level (HDRS) according to Hamilton rating scales, nutritional status assessed by bioimpedancemetry, a degree of manifestation of sleep disorders, eating behaviour typing, eating regimen and daily rhythm determination , level evaluation of glucose, immunoreactive insulin, cholesterol, high-density lipoprotein (HDLP), triglyceride in venous blood, blood glucose tolerance, gustation, life quality assessment. |
|
|
Hydroxymethyl cyclohexylamines Invention relates to novel compounds of formula (1), having affinity to the µ-opioid receptor and the to the ORL1 receptor, a medicinal agent containing said compounds and use thereof to obtain a medicinal agent for treating pain and other diseases. In general formula (1), Y1, Y1', Y2, Y2', Y3, Y3', Y4 and Y4' denote -H; R1 and R2 independently denote -CH3; R3 denotes R0, where R0 denotes C1-8-alkyl; aryl, selected from phenyl which is unsubstituted or mono-substituted with -F, -Cl, -Br, -I, -CN or -OR0, where R0 denotes -C1-3-alkyl; unsubstituted heteroaryl, selected from a 5-member heteroaryl with one S atom as a heteroatom; R4 denotes R0, where R0 denotes aryl, selected from phenyl which is unsubstituted or mono-substituted with -F, -Cl, -Br, -I, -CN or -OR0, where R0 denotes -C1-3-alkyl; 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, mono-substituted with -S(O)2-phenyl; unsubstituted -dihydroisoindolyl or unsubstituted -indolyl; or R4 denotes -OR0 or -SR0, where R0 denotes a cycloaliphatic group selected from -C5-6-cycloalkyl; aryl, selected from unsubstituted phenyl; C1-2-alkylaryl, where aryl denotes phenyl, which is unsubstituted or mono-substituted with -OR0, where R0 denotes -C1-3-alkyl; and R5 denotes -H or -CH3. |
|
Invention relates to compound of formula Ia , where W represents -C(U1)(U2)-C=CH, U1 and U2, which are independently selected from hydrogen; A is selected from group, containing non-substituted phenyl, non-substituted heteroaryl, the same as furanyl, G1, G2 and G3 in formula Ia are independently and separately, in each case, selected from group, containing hydrogen, (C1-C4)alkyl, preferably methyl, L and (C1-C6)alkyl-L, on condition that it is one of G1-G3 in formula Ia that is selected from L and (C1-C6)alkyl-L, and L represents methylsulfonyloxy group, or L represents F, preferably 18F, n=0, m=0, and to its pharmaceutically acceptable salt. Invention also relates to methods of claimed compound obtaining, compositions, which contain such compounds, for treatment and/or diagnostics and/or visualisation of central nervous system diseases or tumours. |
|
Substituted 4-aminocyclohexane derivatives Invention relates to novel 4-aminocyclohexane derivatives, having affinity for the µ- opioid receptor and ORL1 receptor. In formula |
|
Tapentadol compositions for pain management Given invention refers to a sustained-release tapentadol composition also containing a second active agent, wherein the above second active agent is specified in tramadol, pregabalin, gabapentyl, or pharmaceutically acceptable salts thereof. The given composition may be used to prepare a therapeutic agent for pain management. Besides, the present invention refers to a method of managing pain and conditions related to pain, by administering the given composition. The given invention also refers to a kit including a sustained-release tapentadol formulation also containing the second active agent, wherein the above second active agent is specified in tramadol, pregabalin, gabapentyl or pharmaceutically acceptable salts thereof. |
|
Present invention refers to selective sigma-receptor ligands possessing prototypical biphase, antiapoptotic and proapoptotic activity in relation to normal neuronal and cancer cells, to a pharmaceutical composition based thereon, and to using the same for preparing the respective pharmaceutical products. |
|
Pharmaceutical composition for treating urinary disturbances Invention refers to medicine, namely to pharmaceutical compositions for treating urination disturbance that is a syndrome manifested by frequent urination, urinary incontinence, urine retention, etc. The pharmaceutical composition contains an anticholinergic preparation that is diphenyl-acetic acid tropine ester, and preparations of the other mode of action, including Tamsulosin hydrochloride or calcium channels or baclofen in the form of prolonged release tablets or capsules or transdermal dosage forms (gels, ointments or plasters). |
|
|
Compounds representing styrene derivatives for treating ophthalmic diseases and disorders Device refers to new styrene derivatives with the structure formula A in the form of geometrical isomers or tautomers and their pharmaceutical acceptable salts. In structural formula (A) R1 represents hydrogen; R2 represents hydrogen or C1-C6alkyl; R3, R4, R5 and R6 are identical or different and independently represent hydrogen, halogen, C1-C6alkyl or -OR12; R7 represents hydrogen or C1-C6alkyl; R8 represents hydrogen; R9 represents hydrogen, C1-C6alkyl, or -C(=O)R13; R10 represents hydrogen or C1-C6alkyl; Z represents W-Y, wherein W represents -C(R14)(R15)-; Y represents -C(R16)(R17)-; each R12 independently represents hydrogen or C1-C6alkyl; each R13 independently represents C1-C6alkyl; R14 and R15 are identical or different, and independently specified in hydrogen, fluoro, methyl, ethyl, trifluoromethyl, -OH, -OCH3 or -NH2; or R14 and R15 together form oxo; R16 and R17 are identical or different and independently represent hydrogen, halogen, C1-C6alkyl or -OR12. The other radical values are specified in the patent claim. |
|
Stable combined solution of fenoterol hydrobromide and ipratropium bromide Invention relates to medicine and pharmaceutical industry and deals with solution of high-efficient composition in form of solution of active and additional substances, which makes it possible to form aerosol of small particles aimed at penetration in bronchi and pulmonary alveoli. Solution for obtaining medication for inhalational introduction contains fenoterol hydrobromide and ipratropium bromide as active substances, and sodium benzoate, food organic acid, purified water as additional substances with specified ratio of components. |
|
|
Eye drops, which have anti-infectious, anti-inflammatory and anti-allergic action Invention relates to field of medicine, namely to ophthalmology, and can be applied for treatment of different diseases of eyes. Eye drops contain methylene blue, diphenhydramine hydrochloride, naphazoline hydrochloride, hydroxypropylmethylcellulose, boric acid, polyvinylpyrrolidone and distilled water in defined ratio of components. |
|
|
Method of treating chronic prostatitis and erectile dysfunction Invention relates to medicine, namely to urology and may be used for treating category II chronic prostatitis and erectile dysfunction. For this purpose, alpha 1 adrenoceptor blocking agents are prescribed with underlying antibiotics. That is combined with pneumovibromassage of the prostate and pulse vacuum fallostimulation. Besides, there are prescribed prostatilen 5 mg once a day intramuscularly for 10 days and Cytoflavinum in therapeutic dosages: 10.0 or 20.0 in 200.0 or 400.0 ml of 0.9% normal saline intravenously drop-by-drop once a day for 10 days. Then, the scheme provides 2 tablets 2 times a day for 20 days. |
|
|
Pharmaceutical compositions containing s1p receptor modulator Present invention refers to medicine and describes a solid pharmaceutical composition applicable for oral administration and containing: S1P receptor modulator which represents 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol in the free form or in the form of a pharmaceutically acceptable salt or a phosphate thereof and monocrystalline cellulose in the absence of a sugar alcohol. |
|
Invention relates to field of medicine, namely to pharmaceutical industry and deals with solid pharmaceutical composition, possessing high physical strength. Claimed invention also presents method of manufacturing solid pharmaceutical composition. Claimed pharmaceutical composition contains 7 varicoloured types of granules in form of capsule. Granules contain, wt %: nikotinamide 1-35; pyridoxine 0.1-8; calcium pantitenate 0.1-15, thiamin 0.1-30; tryptophan 1-30; tocoferol 0.5-5; ascorbic acid 0.1-50; 5-hydroxyanthranyl acid 0.01-10; Riboflavin 0.1-10; folic acid 0.1-6; cyanocobalomin 0.001-6; isoleucin 0.5-10; leucin 0.5-15; lysine 0.5-20; phenylalanine 0.1-5; threonine 0.1-5.0; valin 0.1-8.0; methionine 0.1-15; lactose 1-4.0; ergocalcioferol 1-95.0 and auxiliary substances for obtaining granules. |
|
Invention refers to a selective antituberculosis agent representing 3-hydrazono-6-(3,5-dimethylpyrazol-1-yl)-1,2,4,5-tetrazine of general formula A |
|
Course of treatment with application of receptor s1p agonist Invention relates to application of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol in free form or in form of pharmaceutically acceptable salt (FTY720) for treatment of autoimmune disease of disorder, where dose of FTY720 during initial period of 4 days constitutes 0.5 mg/1 mg/1.5mg/2 mg, respectively, where after that treatment is continued with day dose equal 0.5 mg. |
|
Group of inventions relates to medicine and deals with pharmaceutical combination of receptor S1P agonist with accompanying agent for treatment of demyelinating diseases except optic nerve neuritis. In claimed pharmaceutical combination agonist of S1P receptor is 2-amino-2-[2-(4-octylphenyl)ethyl]pronane-1,3-diol (FTY720) in free form, in form of pharmaceutically acceptable salt or (FTY720) phosphate, and accompanying agent is interferon, in particular interferon β, or mTOR inhibitor, in particular rapamycin, 40-O-(2-hydroxyethyl)rapamycin or other rapamycin derivative. Claimed is method of treatment, relief or delay of progress of demyelinating disease except optic nerve neuritis, in particular of disseminated sclerosis and Guillain-Barre syndrome, which includes introduction of said combination. Also claimed is application of said combination for manufacturing respective medication. |
|
Combined medication orvium for elimination of symptoms of catarrhal and flu Invention relates to medicine and deals with combined medication for elimination of catarrhal diseases and flu, which contains phenylephrine hydrochloride, N-acetyl-L-hydroxyproline and cetirizine hydrochloride. |
|
|
Oral pharmaceutical composition Pharmaceutical composition applicable for oral administration contains an S1P receptor agonist and mannitol with the composition representing a solid dosage form. Mannitol has a particle specific surface area 1 to 7 m2/g, and the S1P receptor agonist is specified from 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol (FTY720), its pharmaceutically acceptable salt and FTY720-phosphate. |
|
Method for preparing pharmaceutical composition Method for preparing a pharmaceutical composition consists in mixing an S1P receptor agonist - 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or its pharmaceutically acceptable salt with sugar alcohols; the mixture is milled and/or granulated, and then mixed with an oil agent. The method under invention is implemented on high-speed automated equipment and enables producing the compositions with high-level distribution uniformity of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or its pharmaceutically acceptable salt in the composition applicable for oral administration of said S1P receptor agonist. |
|
Pharmaceutical composition for prevention and treatment of depressions Invention refers to a pharmaceutical composition for treating and/or preventing depressions. The pharmaceutical composition contains an active substance presented by a selective serotonin reuptake inhibitor (SSRI) specified in a group of fluoxetine, paroxetine, citalopram, escitalopram, sertraline, fluvoxamine differing by the fact that as an active substance, it additionally contains N-acetyl-5-methoxytryptamine (melatonin) in the following proportions, mg: selective serotonin reuptake inhibitor (SSRI) - 10-30 mg, melatonin - 3-8 mg. The pharmaceutical composition may be presented by a solid dosage form - a tablet, a film-coated tablet, a capsule, by a soft dosage form - a rectal suppository. |
|
|
Invention refers to an agent for treating drug and alcohol dependences which contains an organic colour. The organic colour is specified in a group containing gentian violet, malachite green oxalate, Sudan Black B, Rhodamine 6G or a mixture of said colours and methylene green. The invention also refers to a method of treating drug or alcohol dependence which consists in the introduction of said agent within the dose range of 0.15 mg to 5 g. |
|
|
Present invention refers to medicine and describes a pharmaceutical concentration for dissolution before oral introduction, containing S1P receptor modulator or agonist specified in a group involving 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or proper phosphate, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid, or their pharmaceutically acceptable salts, respectively, and 65 to 99 wt % propylene glycol, and optionally one or more other solvents, one or more aromatisers and/or one or more preserving agents; all the ingredients are added up to 100 wt %. What is also described is a pharmaceutical solution containing the concentrate, the use of the concentrate and the method for treating an individual in need of immune system suppression with the use of said concentrate. |
|
Two-layer composition for continuous release of acetaminophen and tramadol Invention is related to a two-layer composition for acetaminophen and tramadol delivery for at least twelve-month period after the initial introduction. A first layer determines fast release of a part of the composition and contains acetaminophen. A second layer determines continuous release of a part of the composition and contains acetaminophen, tramadol and cross-linked high-amylose starch. The single introduction of the two-layer composition may provide an anaesthising effect for a period of time within the range of a half an hour to approximately one hour after the introduction making at least twelve hours after the initial introduction. |
|
-e-10-oh-nt compositions and method for synthesis and use thereof Invention refers to a composition inhibiting norepinephrine and/or serotonin transporters containing (-) - [ (5-[3-methylaminoprop -(E)-ylidene] - 10, 11 -dihydro- 5H- dibenzo [a,d] cyclohepten-10-ol] in an enantiomeric residue about 90%, and its use for pain management. |
|
Compositions, based on 2-amino-1,3-rpopanediol compounds Invention relates to field of pharmaceutics and deals with pharmaceutical compositions based on organic concentrate for prevention and treatment of transplant rejection, treatment of autoimmune and allergic diseases, which includes 2-amino-1,3-propanediol compounds, selected from 2-amino-2-[4-(3-benzyloxyphenoxy)-2-chlorophenyl]propyl-1,3-propanediol, 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlophenyl]propyl-1,3-propanediol, 2-amino-4-(4-heptyloxyphenyl)-2-methyl-butanol and (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl)-benzo[b]thien-6-yl]butan-1-ol in organic solvent, containing 0-78.9% (wt/vol) of ethanol in propylene glycol or 40-83% (wt/vol) of organic component in water, where organic component contains 10-90 wt/fractions of ethanol and 10-90 wt fractions of propylene glycol, methods of their obtaining and introduction. |
|
Method of treating depressive neurosis Invention relates to medicine, namely to psychiatry, and can be used in treatment of patients with depressive neurosis. For this purpose complex treatment, which includes, which includes introduction of medications and hyperbaric oxygenation, is performed. As medications introduced are paroxetin in dose 20-25 mg internally 1 time per day during 20 days, diazepam in dose 10-12 mg intramuscularly 2 times per day during 20 days, mexidol in daily dose 200-225 mg intravenously by drop infusion during first 10 days, and after that in dose 200-225 mg internally in tablets during the following 10 days, thymogen 0.01% solution in dose 1.2-1.3 ml intramuscularly 1 time per 2 days, 10 injections. Simultaneously with pharmacotherapy during first 10 days of treatment performed is hyperbaric oxygenation with excessive pressure 0.8-1.0 atmosphere with rate of compression and decompression 0.1 atmosphere per minute, with isopression period 40 minutes, 1 time per day. |
|
|
Therapeutic agent for treating fibromyalgia Invention refers to pharmacology and represents an agent for fibromyalgia containing pilocarpine or pilocarpine hydrochloride, and a pharmaceutically acceptable carrier wherein a daily dose of pilocarpine or pilocarpine hydrochloride makes 0.1 mg to 1000 mg. |
|
Method of treating chronic obstructive pulmonary disease accompanied by bronchiectasia Invention refers to medicine, namely pulmonology, and concerns treating chronic obstructive pulmonary disease accompanied by bronchiectasia. That is ensured by the endotracheal introduction of berodual 2 ml, 0.25% novocaine 5 ml, 1% diphenylhydramine 1 ml, and 1% dioxidine 15 ml; the procedure is performed for 15-20 min; the therapeutic course makes 10-15 daily instillations. |
|
|
Invention relates to medicine, namely to cardiology and deals with increase of antihypertensive therapy efficiency and reduction of left ventricle hypertrophy in patients with arterial hypertension of 2-nd degree with high risk of development of cardio-vascular complications (risk 3). For this purpose antihypertensive therapy is performed taking into account prevailing temperament or prevailing part of vegetative nervous system, as well as personality anxiety. With account of said factors elaborated are versions of complex therapy, namely: a) beta-adrenoreceptor antagonist (BAA) and diuretic in average day dose in combination with anxiolytic in minimal day dose; b) BAA and diuteric in minimal day dose; c) ACE inhibitor and diuretic in average day dose in combination with antidepressant in minimal day dose; d) ACE inhibitor and diuretic in minimal day dose and antidepressant in minimal day dose. |
|
Method of anaesthetic management of intraoperative monitoring of spinal function Invention refers to medicine, namely to anaesthesiology, and may be used as an anaesthesia care of surgical correction of severe spinal scoliosis with a high risk of developing neurological complications. For this purpose, 30 minutes prior to the operation, intramuscular pre-medication with Dormicum 0.1 mg/kg and Dimedrol 0.4 mg/kg is required. The anaesthesia is induced by Phentanyl 0.002 mg/kg, Propofol 2.5 mg/kg. The introduction of Nimbex 0.1 mg/kg is followed by the trachea intubation. After the trachea intubation and transition to artificial pulmonary ventilation, loading doses of Clopheline 0.004 mcg/kg and Ketamine 0.25 mg/kg are introduced. Sevorane in the concentration of 4 vol. % immediately follows the trachea intubation and transition to artificial pulmonary ventilation assisted by the air and oxygen flow rate of 4-5 l/min to reach the breath-out sevorane concentration min. 2.6 vol. % (1.04 minimum alveolar concentration). Then the air and oxygen flow rate is decreased to 1 l/min. Artificial pulmonary ventilation is enabled by an anaesthesia apparatus for sevorane delivery in forced pulmonary ventilation mode with the low fresh gas flow rate 1 l/min with minute tidal volume to ensure the breath-out concentration of carbon dioxide within 32-37 mm Hg, the concentration of oxygen in the mixture 40%. The mandatory safety monitoring involves blood pressure, heart rate, electrocardiogram, arterial blood oxygen saturation, mixture oxygen concentration, breath-out carbon dioxide concentration, air and oxygen sevorane concentration, breath-out sevorane concentration, breath-in air and oxygen carbon dioxide and bispectral electroencephalogram and electromyography index recordings. The anaesthesia is maintained by sevorane inhalations 3-1.5 vol. %. (1.2-0.6 minimum alveolar concentration), bolus introductions of Fentanyl 0.004±0.001 mg/kg/h, continuous infusion of Clopheline 0.004 mcg/kg/h, Ketamine 0.25 mg/kg/h and supporting Nimbex 0.05-0.03 mg/kg/h. 30 Minutes before the patient wakes up, sevorane dose is maintained at 1.0-0.8 vol. %, 20 minures before, the Nimbex introduction is completed, 15 minutes before, sevorane delivery is completed, 30 minutes before the waking up, the Fentanyl introduction is completed, while Clopheline and Ketamine are kept to be introduced. The spinal function monitoring is controlled by electroencephalogram activity and nervomuscular conduction as shown by electromyography. Patient contact is considered to be allowed if observing the bispectral electroencephalogram index min. 75-78% and the degree of residual neuromuscular blocks max. 20%. After obtaining the spinal function monitoring data, the bolus introduction of Fentanyl 0.002 mg/kg, Nimbex 0.1 mg/kg, while sevorane is started to be introduced in the concentration of 4 vol. %. Then concentration of Sevorane is reduced to 3-1.5 vol. % (1.2-0.6 minimum alveolar concentration), Clopheline and Ketamine are kept to be infused in the previous dosages. |
|
|
Stabilised pharmaceutical formulation with antimycotic action Invention refers to medicine, more specifically a pharmaceutical formulation in the form of a gel for the local application showing antimycotic activity and containing an effective amount of terbinafine hydrochloride as an active substance and target additives. The formulation contains the target additives as follows: propylene glycol, UV-filter Benzophenone-3 (Escalol 567), cyclomethicone (DC 345), organosilicone elastomer (DC 9045), acrylate emulsion (Salcare SC 80), organosilicone emulsifier PEG-12 Dimethicone (DC 5329), antioxidant (Tinogard NOA), keratolytic urea, preserving agent (Sharomix MCI), trometamol, and purified water. |
|
|
Method of obtaining highly-dispersive paracetamol Invention relates to field of chemical-pharmaceutical industry and deals with method of obtaining highly-dispersive paracetamol by quick cooling of paracetamol solution in system acetone-water with water content 15-30% and paracetamol concentration 80-95% of equilibrium solubility in said mixture at specified temperature by its dispersion into reservoir with liquid nitrogen, either by cooling solution on cooled in liquid nitrogen copper plate with further removal of solvents by sublimation from obtained solid mixture by step-by-step increase of temperature from -196°C to -80°C until acetone is removed completely, then to -35°C in order to disintegrate paracetamol solvate, then to -7°C for disintegration of paracetamol trihydrate and complete removal of ice in vacuumed thermostated vessel at temperature <5·10-2 mm Hg. |
Another patent 2551153.